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Sof overall and recurrence-free survival, longer follow-up is
required, because a full evaluation of the survival endpoints
will require greater maturity of time-to-event data. Thy-
moma is an indolent disease, and longer follow-up is needed
to determine the oncologic outcomes of VATS thymectomy.
In addition, the use of the minimally invasive VATS ap-
proach was started later than use of the open procedure;
thus, the VATS patients require additional observation for
follow-up equivalence.
CONCLUSIONS
To our knowledge, the present series is the largest pub-
lished report comparing the outcomes of a minimally inva-
sive thoracoscopic resection of thymoma with those of an
open technique. VATS resection of early-stage thymoma
appears feasible and safe and was associated with a shorter
hospital LOS. The oncologic outcomes also appear equiva-
lent in the open and VATS groups during intermediate-term
follow-up. Additional follow-up is required to evaluate the
long-term results of thoracoscopic thymectomy for early-
stage thymoma.
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Dr Nasser Altorki (New York, NY). I have a question for you. I
disagree with 4 of your 5 conclusions. I think to talk about onco-
logic validity in thymoma with anything that is less than 5 years,
or preferably 10 years, is probably not correct. Thirty six months
is just way too short of a follow-up to be able to tell that. How
did you follow-up those patients? How carefully did you follow-
up those patients?
Dr Pennathur.Well, we have acknowledged in our conclusions
that longer follow-up is required.We saw all of these patients in the
clinic typically about every 4 to 6months. Now, themyasthenia pa-
tients were also followed very closely by the neurologist, and that
follow-upwas actually a little bit closer, about 3months. So Iwould
say that the myasthenia patients were a little bit more closely fol-
lowed-up compared with the nonmyasthenic thymoma patients.
Dr Altorki. My concern is that I have seen some of those pa-
tients come after transpleural resections, and sometimes youery c March 2011
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Shave to enter the pleural space and they will come back 10 years
later, 12 years later, with pleural implants in the posterior gutters,
basically in both pleural spaces, and that is one reason that I have
found the video-assisted thoracoscopic surgery approach a little bit
intimidating, at least for me.
Dr Pennathur. Yes, I think your point is very valid. I agree that
we need longer follow-up, to fully evaluate the results, which we
have acknowledged in the conclusions. However, there is no series
in the literature to my knowledge evaluating outcomes comparing
a thoracoscopic approach to an open approach at this length of fol-
low-up (36 months), and that is what we have attempted to do.
Also, in terms of the pleural droplet metastasis which does occur
in thymoma, the thoracoscopic approach provides good visualiza-
tion. The first thing you do is explore the chest and we are able to
actually get a good view of the pleura space with the thoracoscopic
approach.
Dr Federico Venuta (Rome, Italy). I was reading your abstract
and I noted in the abstract that you reported 3 patients with positive
margins but in your presentation there was only 1 patient with
a positive margin in the thoracoscopic group.
Dr Pennathur.Yes. That is an error in the abstract. It is 1 patient
with a positive margin.
Dr Venuta. And if I may ask another question, how did you di-
vide these patients with the 2 approaches? How did you decide
who received the open approach and who received the thoraco-
scopic approach?
Dr Pennathur. This is certainly not a randomized study, so
there is clearly a selection bias in terms of the surgeon and the pa-
tient in deciding the approach. In general, if the thymoma is less
than about 5 cm or so, particularly in the early stage of performing
these thoracoscopic thymectomies, we preferred to do those thy-
momas that looked small and encapsulated. Some of them on final
pathology, however, had capsular invasion, putting them as a stage
II. When there was concern about invasion into adjacent structures
or bigger lesions, those were handled by an open approach. The
largest lesion in this series in the video-assisted thoracoscopic sur-
gery approach was 5.6 cm and the median was 3.6 cm. So I think it
is the size, the appearance on the CT scan, relationship to adjacent
structures, and, of course, there is a selection bias in terms of the
surgeon who is doing the case. This is a retrospective study. It’s
not a prospective randomized study.
Dr Venuta. What are your indications for postoperative radio-
therapy?
Dr Pennathur.Well, I know this is being debated. Dr Wright at
Massachusetts General had presented a series on the usefulness of
radiation for stage II and a similar series has been presented by Dr
Singhal from the University of Pennsylvania questioning the value
of radiation. In our institution, if it’s a stage II or higher, we give
consideration for radiation therapy. Other considerations for radi-
ation include positive margins and more advanced tumors. But I
think this is something is being questioned. The recurrences occur
many times in the pleura, as Dr Altorki pointed out, so radiating
them in the chest—the thymic bed—may not entirely be effective.The Journal of Thoracic and CaDr Raphael Bueno (Boston, Mass). Nice paper and I think it
will take time to figure out what the answer is. You had another pa-
rameter besides oncologic, which is the recurrence of myasthenia.
Did that differ in the 2 groups?
Dr Pennathur.No, it did not differ. The bottom linewas that the
Osserman score showed a significant improvement in both the
groups. Nine out of 11 patients with myasthenia improved. The
Osserman score had a mean drop of negative 2, which is an overall
improvement. We did not find significant differences between the
surgical groups.
Dr Michael Jaklitsch (Boston, Mass). My personal inhibition
against doing a thoracoscopic thymectomy for thymoma is from
my personal experience, in that in dissecting out the gland, I can
see micro-defects in the capsule of the gland, and what makes
you stage I is having that gland intact. I have used a variety of tech-
niques, but I can see these little nicks, which I do not get with a par-
tial sternotomy. Am I different from you and you have a technique
that you can get the gland out without capsular nicks, or am I like
you and we are both getting capsular nicks but you are showing me
oncologically that those nicks do not matter?
Dr Pennathur.Well, I think that there are various ways of mo-
bilizing the thymus, and oneway, for example, described byDrAu-
gasthian at the Society of Thoracic Surgeons, which is similar to
ours, is we do not handle the tumor first. Try to go toward more
of the normal thymus, mobilize, and create the plane before obvi-
ously going where the mass is and before trying to mobilize the
mass initially. So, if you start from the normal tissue and start mo-
bilizing from there, that helps. The other thing that we have done
over the years with the evolution of the technique is that we have
used a bilateral approach. You get a very good look at the left
side. We start mobilization on the left side, and then as we move
along, the patient is placed supine, which also helps with easy con-
version, if needed; and then we go to the right side, and, again, you
can take from the normal tissue and then mobilize it, and then you
will be able to potentially avoid some of those nicks. But it can be
a problem. One has to handle the capsule very carefully.
Dr Thomas Rice (Cleveland, Ohio). Beyond the short follow-
up and the few events, you have to ask: Are these comparable
groups? So when you come to doing your multivariable analysis
when you get enough events, even if you do not have enough pa-
tients, you should put the propensity score in the multivariable
analysis to see if it is a fair comparison. It probably is not.
Dr Pennathur. Dr Rice, thank you for your comments. Yes, we
can certainly consider doing that—trying to adjust for the various
variables. One thing we found was that size was bigger in the open
group.
Dr Nasser Altorki (New York, NY). Perhaps you have done it
already, but let me just make a pitch for the partial sternal splits,
which are ideally suited for small thymomas of the superior medi-
astinum, because I do agree that your length of stay can probably
be shortened.
Dr Pennathur.Yes. Thanks for your comments. I want to thank
the Society for the opportunity to present this paper.rdiovascular Surgery c Volume 141, Number 3 701
